Simulations Plus IncNASDAQ:SLP
- LAST PRICE45.4500
- TODAY'S CHANGE (%)0.7600 (1.7006%)
- Bid / Lots43.6300/ 1
- Ask / Lots48.3900/ 1
- Open / Previous Close44.9700 / 44.6900
- Day Range
- 52 Week Range
- Volume55,080
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLP |
|---|---|---|
| 09:32 ET | 423 | 44.97 |
| 10:14 ET | 104 | 45.05 |
| 10:19 ET | 707 | 44.9538 |
| 10:35 ET | 132 | 45.074 |
| 10:39 ET | 100 | 45.07 |
| 11:22 ET | 136 | 45.01 |
| 11:31 ET | 200 | 44.99 |
| 11:58 ET | 500 | 45.18 |
| 12:05 ET | 200 | 45.25 |
| 12:20 ET | 181 | 45.4299 |
| 12:30 ET | 448 | 45.32 |
| 12:48 ET | 300 | 45 |
| 12:50 ET | 100 | 45.135 |
| 01:06 ET | 100 | 45.135 |
| 01:08 ET | 1000 | 45.135 |
| 01:10 ET | 2112 | 45.22 |
| 01:14 ET | 200 | 45.2 |
| 01:15 ET | 200 | 45.34 |
| 01:28 ET | 100 | 45.45 |
| 01:32 ET | 100 | 45.37 |
| 01:51 ET | 303 | 45.33 |
| 01:55 ET | 117 | 45.387 |
| 01:57 ET | 100 | 45.36 |
| 02:08 ET | 1200 | 45.49 |
| 02:11 ET | 100 | 45.525 |
| 02:13 ET | 2577 | 45.515 |
| 02:15 ET | 1109 | 45.45 |
| 02:40 ET | 344 | 45.37 |
| 02:44 ET | 200 | 45.41 |
| 03:02 ET | 100 | 45.34 |
| 03:03 ET | 100 | 45.19 |
| 03:05 ET | 153 | 45.06 |
| 03:12 ET | 200 | 45.19 |
| 03:18 ET | 200 | 45.16 |
| 03:36 ET | 300 | 45.2 |
| 03:38 ET | 300 | 45.27 |
| 03:39 ET | 661 | 45.215 |
| 03:43 ET | 300 | 45.29 |
| 03:50 ET | 500 | 45.26 |
| 03:52 ET | 1200 | 45.286 |
| 03:54 ET | 372 | 45.35 |
| 03:56 ET | 520 | 45.4499 |
| 03:57 ET | 820 | 45.41 |
| 03:59 ET | 1725 | 45.45 |
Apr 4, 2024
DJ Simulations Plus Shares Rise 27% Following FDA's License Renewal for Dilisym Software Platform, from 11:52AM ET on Thursday Apr 04, 2024 by Dow Jones
11:52AM ET on Thursday Apr 04, 2024 by Dow JonesU.S. FDA Renews DILIsym(R) Software Licenses for 7th Year, from 8:30AM ET on Thursday Apr 04, 2024 by Dow Jones
8:30AM ET on Thursday Apr 04, 2024 by Dow Jones
Apr 3, 2024
DJ Stocks to Watch: Levi Strauss, BlackBerry, Simulations Plus, from 7:28PM ET on Wednesday Apr 03, 2024 by Dow Jones
7:28PM ET on Wednesday Apr 03, 2024 by Dow JonesDJ Simulations Plus Shares Climb 7% After 2Q Revenue Beat, from 6:01PM ET on Wednesday Apr 03, 2024 by Dow Jones
6:01PM ET on Wednesday Apr 03, 2024 by Dow JonesSimulations Plus Reports Second Quarter Fiscal 2024 Financial Results, from 4:34PM ET on Wednesday Apr 03, 2024 by Dow Jones
4:34PM ET on Wednesday Apr 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Simulations Plus Inc | 893.1M | 87.8x | +3.18% |
Standard BioTools Inc | 934.6M | -2.6x | --- |
Neuropace Inc | 384.6M | -10.6x | --- |
Coretag Inc | 1.1B | -28,588.4x | --- |
MaxCyte Inc | 387.3M | -10.0x | --- |
Quanterix Corp | 595.1M | -18.1x | --- |
Company Information
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Contact Information
- Headquarters
- 42505 10Th Street WestLANCASTER, CA, United States 93534-7059
- Phone
- 661-723-7723
- Fax
- 661-723-5524
Executives
- Chairman of the Board
- Walter Woltosz
- Chief Executive Officer
- Shawn O'Connor
- Chief Financial Officer, Chief Operating Officer, Secretary
- William Frederick
- President - PBPK, Regulatory Strategies, Cheminformatics Solutions
- John Dibella
- President - Clinical Pharmacology and Pharmacometric Services
- Jill Fiedler-Kelly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $893.1M |
|---|---|
Revenue (TTM) | $64.7M |
Shares Outstanding | 20.0M |
Dividend Yield | 0.53% |
Annual Dividend Rate | 0.2400 USD |
Ex-Dividend Date | 04-26-24 |
Pay Date | 05-06-24 |
Beta | 0.68 |
EPS | $0.52 |
Book Value | $8.53 |
P/E Ratio | 87.8x |
Price/Sales (TTM) | 13.8 |
Price/Cash Flow (TTM) | 60.8x |
Operating Margin | 12.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
